These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28718166)

  • 1. Can Long-term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
    Presicce F; De Nunzio C; Tubaro A
    Curr Urol Rep; 2017 Sep; 18(9):72. PubMed ID: 28718166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late?
    Presicce F; DE Nunzio C; Gacci M; Sosnowsky R; Lombardo R; Porpiglia F; Tubaro A
    Minerva Urol Nefrol; 2017 Jun; 69(3):242-252. PubMed ID: 27879967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Implications for the Early Treatment of Benign Prostatic Enlargement (BPE): a Systematic Review.
    Presicce F; De Nunzio C; Tubaro A
    Curr Urol Rep; 2018 Jul; 19(9):70. PubMed ID: 29987480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is early benign prostatic hyperplasia (BPH) treatment worthwhile?
    Presicce F; De Nunzio C; Tubaro A
    Urologia; 2017 Aug; 84(3):142-147. PubMed ID: 28665456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaporize, anatomically vaporize or enucleate the prostate? The flexible use of the GreenLight laser.
    Cindolo L; Ruggera L; Destefanis P; Dadone C; Ferrari G
    Int Urol Nephrol; 2017 Mar; 49(3):405-411. PubMed ID: 28044238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Outcomes of Medical Management and Minimally Invasive Surgical Techniques for Lower Urinary Tract Symptoms due to BPH.
    Sterling J; Farber N; Gupta NK
    Curr Urol Rep; 2019 Apr; 20(6):29. PubMed ID: 30989392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate.
    Ingimarsson JP; Isaksson HJ; Sigbjarnarson HP; Gudmundsson J; Geirsson G
    Scand J Urol; 2014 Feb; 48(1):73-8. PubMed ID: 23924152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia.
    Vande Griend JP; Linnebur SA
    Ann Pharmacother; 2012 Sep; 46(9):1245-9. PubMed ID: 22851743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.
    Welliver C; Feinstein L; Ward JB; Fwu CW; Kirkali Z; Bavendam T; Matlaga BR; McVary KT;
    J Urol; 2020 Jan; 203(1):171-178. PubMed ID: 31430232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventional therapies for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Seitz M; Bader M; Tilki D; Stief C; Gratzke C
    Minerva Urol Nefrol; 2012 Jun; 64(2):123-33. PubMed ID: 22617306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature.
    Amparore D; De Cillis S; Volpi G; Checcucci E; Manfredi M; Morra I; Di Dio M; Fiori C; Porpiglia F;
    Curr Urol Rep; 2019 Jul; 20(8):47. PubMed ID: 31278441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.